Current Report Filing (8-k)
May 15 2023 - 10:06AM
Edgar (US Regulatory)
0000822370
false
0000822370
2023-05-15
2023-05-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 15, 2023
Emmaus Life Sciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35527 |
|
87-0419387 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
21250 Hawthorne Boulevard, Suite 800, Torrance, CA |
|
90503 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code (310) 214-0065
(Former name or former address, if changed, since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
None |
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operation and Financial Condition.
On May 15, 2023, Emmaus Life
Sciences, Inc. issued a press release announcing its results of operations and financial condition as of and for the three months ended
March 31, 2023. A copy of the press release is included as Exhibit 99.1 to this Current Report and incorporated herein by reference.
The
information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly provided in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
See the accompanying Index to Exhibits, which information
is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: May 15, 2023 |
Emmaus Life Sciences, Inc. |
|
|
|
|
By: |
/s/ YASUSHI NAGASAKI |
|
|
Name: |
Yasushi Nagasaki |
|
|
Title: |
Chief Financial Officer |
INDEX TO EXHIBITS
Exhibit Number |
|
Description |
99.1 |
|
May 15, 2023 Press Release |
104 |
|
Cover Page Interactive Date File (embedded within Inline XBRL document) |
3
Strive 500 ETF (AMEX:STRV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Strive 500 ETF (AMEX:STRV)
Historical Stock Chart
From Aug 2023 to Aug 2024